Kyle Munz

A retrospective, exploratory analysis identifies biomarkers predictive of spinal muscular atrophy (SMA) response to nusinersen and suggests the efficacy of using machine learning algorithms to anticipate patient outcomes.

A Biologics License Application has been submitted to the FDA review for sotatercept in the treatment of pulmonary arterial hypertension.

In a recent review, researchers overviewed the challenging aspects of treating pulmonary arterial hypertension (PAH), highlight the genetic and etiological variability, and advocate for research to expand personalized medicine.

A retrospective analysis suggested that administering rituximab to patients with rheumatoid arthritis complicated by lymphoma, systemic vasculitis, or extra-articular lesions was associated with improved outcomes.

Three new novel treatments have shown promise in the treatment of multiple sclerosis (MS), including the potential to target neuroinflammation at its source.

Presenters at American Society of Nephrology Kidney Week 2023 highlighted the importance of understanding the barriers faced by the LGBTQ+ community that impact kidney outcomes and the need to gather better data for studying these issues.

Presenters at the American Society of Nephrology (ASN) Kidney Week 2023 highlighted the exciting new technologies that nephrology research has developed to improve patient outcomes, quality of life, and approaches to care.

Posters at ASN Kidney Week 2023 explored the economic burden brought on by chronic kidney disease (CKD) and further validated the Klinrisk model’s ability to predict progressive forms of CKD.

Presenters at ASN Kidney Week 2023 emphasized the importance of patient education, awareness, and advocacy in the realm of kidney transplantation.

Two posters presented at Kidney Week 2023 evaluated the global state of chronic kidney disease (CKD) and shed light on delays in CKD diagnoses in the United States.

Presenters at the American Society of Nephrology's Kidney Week 2023 discussed the past, present, and future of pediatric chronic kidney disease, as well as explored the obstacles and solutions for effective trial designs.

In a study driven by simulation modeling, researchers elaborated on policies that contribute to widening health disparities affecting Indigenous communities.

Data from the SPHERE registry revealed racial and ethnic discrepancies in disease severity, comorbidities, and outcomes experienced by patients with pulmonary arterial hypertension (PAH) receiving selexipag.

The American Society of Nephrology (ASN) Kidney Week 2023 will take place in Philadelphia, Pennsylvania, from November 2-5, as experts from across the globe gather to discuss the latest innovations in renal care and current issues facing the field.

Researchers have developed a new line method (NLM) that showcased benefits for genetic screening in spinal muscular atrophy (SMA).

Results from a retrospective, matched cohort study suggested that valvular heart disease and aortic stenosis may contribute to disparities in cardiovascular disease–related mortality in patients with rheumatoid arthritis (RA).

Researchers used real-world data to further validate the use of selexipag in the management of pulmonary arterial hypertension (PAH).

A phase 3, randomized, parallel-group trial showcased the efficacy of internet-based cognitive behavioral therapy (iCBT) for combatting depressive symptoms brought on by multiple sclerosis (MS).

Helen Shih, MD, MS, MPH, FASTRO, Massachusetts General Hospital, weighs the risks and benefits of treating or postponing treatment of low-grade gliomas.

Tina Cascone, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses the impact of the CheckMate 77T study on the treatment approach for non–small cell lung cancer (NSCLC).

Thomas Powles, MD, MBBS, MRCP, from Barts Cancer Centre, shares insights from the EV-302/KEYNOTE-A39 trial and its implications for the future of enfortumab vedotin and pembrolizumab (EV+P) combination therapy for urothelial carcinoma.

Health equity coverage appearing in the October 2023 issue of Evidence-Based Oncology.

Kevin Kalinsky, MD, MS, of Glenn Family Breast Center, gives insight into the real-world data supporting the use of sacituzumab govitecan-hziy in the treatment of triple-negative breast cancer (TNBC).

Max Parmar, professor of medical statistics and epidemiology at University College London, unpacks what clinicians and patients can gain from the application of multiarm multistage (MAMS) trials.

Pawel Sobczuk, MD, PhD, of the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, previews the upcoming ESMO Congress 2023 in Madrid, Spain.

In this prospective study, respiratory monitoring of patients with spinal muscular atrophy (SMA) benefited from the use of diaphragm ultrasound imaging.

In an observational cohort study, factors such as education, income, and marital status correlated with MS severity outcomes.

A retrospective, population-based study reveals a possible association between COVID-19 infection and autoimmune and autoinflammatory outcomes.

A co-expression network analysis pinpoints different gene expressions that can potentially predict rheumatoid arthritis (RA) outcomes during pregnancy.

Through a multitude of assessment tools, findings suggest that lower amounts of physical activity directly correlate with higher rates of fatigue in patients with relapsing-remitting multiple sclerosis (MS).